Skip to content
TrialScanner

NCT03575052

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Phase 3CompletedACADLead

Registry record

Lead sponsor
ACADIA Pharmaceuticals Inc.
Conditions
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Primary completion
May 6, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03575052 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03575052: A Safety Study of Pimavanseri... | TrialScanner